Vlădăreanu Ana Maria, Voican Irina, Bumbea H, Vasile Daniela, Radesi Sânziana, Coriu D, Coliţa Adriana, Tălmaci Rodica, Ilea Anca
Department of Hematology, Emergency University Hospital Bucharest, "Carol Davila" University of Medicine and Pharmacy Bucharest-UMCFD, Romania.
Rom J Intern Med. 2010;48(1):73-9.
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder in which the diagnosis is confirmed by detection of a genetic marker: Philadelphia (Ph) chromosome in almost 90% of cases. Some of Ph1 negative patients, nevertheless, test positive for the abnormal gene, or the abnormal protein associated with this chromosome, when more sensitive studies, such as PCR or FISH are used and nowadays the diagnosis of CML is based, not only on cytogenetic, but also on molecular analysis. The better understanding of the CML biology provided by the latest researches requires a deeper knowledge about the epidemiologic data in each geographic area, so the compiling of a National and/or European Registry for CML patients, that represents one of the aims of this study, became a stringent matter in our days; it can offer valuable data concerning the real incidence of this disease in Romania and can provide the basics for establishing long-term budgetary strategies.
慢性髓性白血病（CML）是一种造血干细胞疾病，几乎90%的病例通过检测一种基因标志物——费城（Ph）染色体来确诊。然而，一些Ph1阴性患者，当采用更敏感的研究方法（如PCR或FISH）时，其异常基因或与该染色体相关的异常蛋白检测呈阳性。如今，CML的诊断不仅基于细胞遗传学，还基于分子分析。最新研究对CML生物学的更好理解需要更深入了解每个地理区域的流行病学数据，因此，编制一份CML患者国家和/或欧洲登记册（这是本研究的目标之一）在当今成为一件紧迫的事情；它可以提供有关罗马尼亚这种疾病实际发病率的宝贵数据，并可为制定长期预算策略提供基础。
